Zhenghua Wu

5PUBLICATIONS
2CO-AUTHORS
PharmacogenomicsMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 18, 2026
Gastrointestinal and skin safety evaluation of pirfenidone versus nintedanib: an analysis of real-world pharmacovigilance and randomized controlled trials.

|Jun 09, 2025
An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti-Angiogenic Agents for Therapy: A Case Report.

Li Wang, Jiaqi Wu, Ping Shao

|Dec 19, 2024
Safety of talimogene laherparepvec: a real-world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS).

Yifan Hong, Kebin Cheng, Han Qu

|Jan 03, 2024
Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials.

Li Wang, Yibo Fei, Han Qu

|Jun 17, 2015
Anterior gradient 2 is a binding stabilizer of hypoxia inducible factor-1α that enhances CoCl2 -induced doxorubicin resistance in breast cancer cells.

Zheqi Li, Qi Zhu, Lingyun Hu

Pageof 1

Frequent Collaborators

1 joint publications

Yifan Hong

1 joint publications

Kebin Cheng